PRMT5 and colorectal cancer: Accumulating evidence indicates that PRMT5 functions as an oncogene in colorectal cancer and that its cancer‐promoting function depends on its methyltransferase activity,[26, 27, 28] suggesting that PRMT5 is a potential target for cancer therapy.